Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus
Genmab A/S shares fell 3.3% to $30.44 in New York after the company dropped further development of acasunlimab, a late-stage cancer drug, following a portfolio review. Genmab said the move does not affect its 2025 guidance and will focus on other pipeline drugs. The company also completed its acquisition of Merus N.V., paying $97 per share in a tender offer. Merus requested Nasdaq delist its stock after the merger.
